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Background: Multiparameter flow cytometry (FC) is essential in the diagnostic work-up and
classification of primary immunodeficiency (PIDs). The EuroFlow PID Orientation tube (PIDOT)
allows identification of all main lymphocyte subpopulations in blood. To standardize data
analysis, tools for Automated Gating and Identification (AG&I) of the informative cell
populations, were developed by EuroFlow. Here, we evaluated the contribution of these
innovative AG&I tools to the standardization of FC in the diagnostic work-up of PID, by
comparing AG&I against expert-based (EuroFlow-standardized) Manual Gating (MG) strategy,
and its impact on the reproducibility and clinical interpretation of results.
Methods: FC data files from 44 patients (13 CVID, 12 PID, 19 non-PID) and 26 healthy
donor (HD) blood samples stained with PIDOT were analyzed in parallel by MG and AG&I,
using Infinicyt™ software (Cytognos). For comparison, percentage differences in absolute
cell counts/µL were calculated for each lymphocyte subpopulation. Data files showing
differences >20% were checked for their potential clinical relevance, based on age-
matched percentile (p5-p95) reference ranges. In parallel, intra- and inter-observer
reproducibility of MG vs AG&I were evaluated in a subset of 12 samples.
Results: The AG&I approach was able to identify the vast majority of lymphoid events
(>99%), associated with a significantly higher intra- and inter-observer reproducibility
compared to MG. For most HD (83%) and patient (68%) samples, a high degree of
agreement (<20% numerical differences in absolute cell counts/µL) was obtained between
MG and the AG&I module. This translated into a minimal impact (<5% of observations) onorg November 2020 | Volume 11 | Article 5846461
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Frontiers in Immunology | www.frontiersin.the final clinical interpretation. In all except three samples, extended expert revision of the
AG&I approach revealed no error. In the three remaining samples aberrant maturation
and/or abnormal marker expression profiles were seen leading in all three cases to
numerical alarms by AG&I.
Conclusion: Altogether, our results indicate that replacement of MG by the AG&I module
would be associated with a greater reproducibility and robustness of results in the
diagnostic work-up of patients suspected of PID. However, expert revision of the
results of AG&I of PIDOT data still remains necessary in samples with numerical
alterations and aberrant B- and T-cell maturation and/or marker expression profiles.Keywords: flow cytometry, immunophenotyping, primary immunodeficiencies, automated gating,
standardization, EuroFlowINTRODUCTION
Primary immunodeficiency (PIDs) comprises a clinically
heterogeneous group of rare disorders with defects in the
innate and/or adaptive immune system. Due to the
dysfunctional immune system, patients can suffer from a wide
variety of clinical manifestations, including severe, recurrent and
opportunistic infections, auto-inflammation and auto-immunity
(1–3). Since delayed diagnosis causes higher morbidity and
mortality, fast and efficient PID diagnosis, classification and
risk assessment is critically important.
Multicolor flow cytometric (FC) immunophenotyping has
become a key tool in the diagnostic work-up and classification of
PID (1, 3–7). FC has the advantage of providing fast, widely
accessible and relatively low-cost diagnostic screening (8) based
on a wide range of assays devoted to immunophenotypic
identification and enumeration of specific (sub)populations of
blood lymphocytes (e.g. B, T and NK cell subsets), quantitative
evaluation of disease-associated protein expression profiles—e.g.
Wiskott-Aldrich syndrome protein screen (WASP), CD40/
CD40Ligand expression for hyper IgM syndromes-, functional
assays (e.g. lymphocyte/T-cell proliferation) and analysis of
specific signaling pathways (e.g. phosphorylation of STAT
proteins) (2, 7–9).
Despite the clinical relevance of FC in the diagnosis and
classification of PID, standardization of specific FC assays across
distinct laboratories still remains a challenge. Thus, most
published FC data on PID are limited to single center datasets
which may not be directly applicable in other centers. Generation
of reproducible and comparable data in multicenter settings is
required for (inter)national data exchange and integration,
creation of larger datasets of patient samples and better
identification and definition of the altered immunophenotypic
patterns associated with specific PID diagnostic categories.
In the past years, the EuroFlow consortium developed a
diagnostic algorithm together with fully standardized antibody
combinations (preferably used as dried format reagent mixes)
(10) and analytical FC procedures for the diagnostic screening
and classification of PID of the lymphoid system (6). In the
proposed EuroFlow approach, the PID orientation tube (PIDOT)
plays a central role in case of suspicion of PID, as recently validatedorg 2in a selected cohort of genetically defined PID patients (4). Overall,
PIDOT allows unequivocal and reproducible identification of >20
different leucocyte populations (including 15 T, B andNK lymphoid
subpopulations) in blood, when more than a million cells are
evaluated. Interpretation of such data using the classical (2-
dimensional-based) expert-guided Manual Gating (MG)
approaches (i.e. Boolean gating strategies) is time-consuming and
highly subjective, as it relies on the operator’s gating decisions,
knowledge and expertise. Thereby, MG strategies may result in
disturbing levels of variability and more limited reproducibility of
FC data analysis, depending on the knowledge and experience of
each individual expert (11–14). In order to avoid such variability
introduced during data analysis, the EuroFlow consortium has
developed innovative Automated Gating and Identification
(AG&I) approaches and software tools (14), which can be directly
applied to the analysis of FC standard data files of blood samples
stained with the PIDOT. This tool is based on the combined use of
clustering algorithms and big data-based classification approaches,
including direct comparison of individual clusters of events per
interrogated sample against i) a fully annotated database of FC data
files from healthy individuals stained according to the same
standard operating procedures (SOPs), and ii) reference values
based on a large dataset of hundreds of age-matched healthy
donors that includes samples from controls between 0 days
(neonatal) and 89 year-old subjects (4, 14).
In this study, we evaluated the contribution of the AG&Imodule
available in the Infinicyt software (Cytognos Sl, Salamanca, Spain),
in combination with the PIDOT antibody panel and database, for
an increased reproducibility and standardization of multiparameter
FC analysis of lymphocyte populations in blood of patients
suspected of PID, compared to the classical EuroFlow-
standardized MG strategy. In parallel, we also evaluated the
potential impact of the new AG&I tool vs. the classical MG
approach on the clinical interpretation of PIDOT results.MATERIALS AND METHODS
Sample Collection
FC PIDOT data files of peripheral blood (PB) samples from 44
patients, collected in a routine context of PID suspicion at theNovember 2020 | Volume 11 | Article 584646
Linskens et al. Automated Gating for FC PID ScreeningHematology Laboratory of the Ghent University Hospital
between November 2016 and March 2018, were included in
this study. From these patients, 13 were diagnosed with
common variable immunodeficiency (CVID) according to the
ESID criteria (9) (M/F ratio: 8/5; age range: 7–67y), and 12 with
other PID (M/F ratio: 5/7; age range: 1–12y; two patients
with Shwachman–Bodian–Diamond Syndrome [SBDS]; two
with KMT2A deficiency; two with myeloperoxidase (MPO)
deficiency; one patient with tumor necrosis factor receptor-
associated periodic syndrome [TRAPS]; one with KMT2D
deficiency; one with adenosine deaminase (ADA) deficiency;
one with IRAK4 deficiency and two with mannose-binding
lectin (MBL) deficiency); the other 19 cases corresponded to
non-PID patients with PID suspicion at time of sampling in
whom the diagnosis of PID was ruled out ([non PID]; M/F
ratio: 12/7; age range: 11m–50y). In addition, FC PIDOT data
files from 26 healthy donors (HD) (M/F ratio: 10/16; age range:
20–58y) collected at Leiden University Medical Center (n=16)
and at the Hematology Laboratory of the Ghent University
Hospital (n=10) were included in the study (15). The study was
approved by the local ethics committee of the Ghent University
Hospital, Belgium (approval 2016/1137). Informed consent
from the adult healthy volunteers included in the study was
obtained at the time of blood sampling at the participating
centers (15).Staining Procedures, Instrument Set-Up,
and Data Acquisition
PB samples were collected in BD Vacutainer tubes containing
K2EDTA (Becton/Dickinson, San Jose, CA). For each sample, a
white blood cell (WBC) count was determined on a Sysmex XP-300
hematology analyzer (Sysmex Corporation, Kobe, Japan). For the
immunophenotypic studies non-nucleated red cells were lysed prior
to staining, strictly following the EuroFlow bulk lyse SOP (available
at www.EuroFlow.org), as described elsewhere (16, 17).
Subsequently, a stain- wash protocol was performed. Thus, the
remaining cell pellet in a volume of 100µL, was stained for 30
minutes in the dark (room temperature [RT]) with the EuroFlow
PIDOT monoclonal antibody combination, as previously described
(liquid format) (4). Afterwards, 2mL of BD FACS™ Lysing solution
–Becton/Dickinson Biosciences (BD)- diluted 1/10 (v/v) in distilled
water, was added and the cell suspension was incubated for another
10 minutes at RT in the dark. Afterwards, cells were washed and the
cell pellet was re-suspended in 300µL of washing buffer. Staining
and data acquisition of all samples were performed within 24h after
blood collection.
Datawere acquiredonBDFACSCanto™ IIflowcytometers (BD)
at the collection sites. In both centers, instrument settings and data
acquisition were performed according to the EuroFlow guidelines
available at www.EuroFlow.org (11). Standard instrument settings
were monitored by BD™ Cytometer Setup and Tracking (CS&T)
beads (BD) and eight-peak Rainbow bead calibration particles
(Spherotech, Lake Forest, IL). For each sample at least 106 total
events were acquired at low-medium speed. Subsequently, data were
exported as an FC standard-file for further analysis. As per the
EuroFlow standard instrument setting and calibration SOPs, furtherFrontiers in Immunology | www.frontiersin.org 3manual compensation for optimization of measurements of
individual samples was not required.
Data Analysis
All FC standard data files were analyzed using Infinicyt™
Software (version 2.0.1b, Cytognos SL, Salamanca, Spain) both
manually (MG strategy) and automatically (AG&I) using the
Infinicyt™ AG&I module and the EuroFlow PIDOT database,
with a special focus on the lymphoid populations.
MG was based on the previously published EuroFlow PIDOT
guidelines (4, 6). Briefly, gating of the lymphoid populations was
performed after excluding debris and cell doublets based on
sideward light scatter area (SSC-A)/forward light scatter area
(FSC-A) and FSC Height (FSC-H)/FSC-A bivariate dotplots,
respectively. B-cells were identified based on their unique
CD45hi CD19+ CD3- CD45RA+ phenotype and FSClo SSClo
characteristics. Further identification of B-cell subpopulations
was based on the levels of expression of CD27, IgM and IgD. In
turn, T-cells were identified based on a CD45hi CD3+ and FSClo
SSClo phenotype. After gating TCRgd+ T-cells, the CD4+, CD8+
and CD4- CD8- TCRgd- T-cell subpopulations were identified.
Subsequently, the distinct maturation-associated subsets of
CD4+ and CD8+ TCRgd- T-cell subpopulations were further
identified based on their unique levels of expression of CD27 and
CD45RA. Finally, NK-cells were defined as CD45hiCD19-CD3-
CD16&CD56hiCD45RAlo to + FSC-Alo SSC-Alo cells. More
details on the MG strategy used for the identification of the
lymphoid populations are provided in Table 1.
In parallel with the MG strategy, all FC standard data files were
also analyzed with the AG&I module of Infinicyt™. The AG&I
module compares each FC standard data file with a reference
database of healthy controls using the automated gating and
classification algorithms, as previously described in detail (18, 19).
This automated analysis included a first clustering step of all
individual events in the data file, followed in a second step by
classification of the resulting clusters of events into the cell
populations identified a priori in the database, according to their
characteristics in the multidimensional space generated by all the
parameters evaluated. Input of patient’s age and WBC counts was
required before the automated process could be started. During
automated data processing, most events are automatically assigned
to the different cell populations with only a few remaining
unassigned clusters of events (= “checks”). For these latter groups
of alarmed events, the AG&I module proposes one or more
populations to which they might correspond, but definitive
assignment to a given cell population must be done manually by
an expert. Once the alarmed events have been checked by the
expert, the software provides an automated report indicating the
normal range in age-matched controls, with a “remark” for each cell
population with values out of the normal range, using previously
published reference values (4, 6). In this study, those events
automatically assigned to a given cell population were not re-
evaluated or re-classified manually to mimic the optimal routine
situation, unless stated otherwise. Following the automated gating
process, the percentage of each cell population from both its parent
population and all WBC, was automatically calculated, recorded
and stored by the Infinicyt™ software. Absolute cell counts/µL wereNovember 2020 | Volume 11 | Article 584646





Comparison Between the MG Strategy and the AG&I
Approach
Absolute cell counts/µL obtained with the MG and AG&I
strategies were compared for each cell population. The
percentage difference between the counts for each cell
population obtained with the two strategies was calculated by
the following formula:
(absolute count=mL) MG − (absolute count=mL) AG& I
(absolute count=mL)MG
x100
According to the International Standard EN ISO 15189 (20), the
two gating methods were considered to be equivalent whenever the
percent difference was <20%. Nevertheless, for the less abundant
subpopulations with relatively wide reference intervals, the
application of the <20% difference criterion may be clinically
irrelevant. Because of this, for all lymphoid subpopulations with
>20% differences we applied an additional criterion that relied on
the impact on the final clinical interpretation, based on comparison
of each of the two values against age-matched reference percentile
(p5–p95) ranges as determined on a group of 250 HD (4).
Differences in interpretation of the results after application ofFrontiers in Immunology | www.frontiersin.org 4these age-matched reference values were considered as ‘clinically
relevant’ and triggered a more detailed revision of both the AG&I
(including a revision of the automatically assigned events whenever
necessary) and MG analyses.
Intra- and Inter-Observer Reproducibility
Twelve samples (three samples from each patient group and the HD
group) out of the 70 samples analyzed were randomly chosen to
document the impact of the use of the AG&I software tools vs MG,
on intra-observer and inter-observer reproducibility of data analysis.
For evaluation of intra-observer reproducibility, MG and
AG&I were performed five times by the same observer (EL) on
those 12 samples selected as described above. For inter-observer
reproducibility, MG and AG&I were performed on the same 12
samples by five different observers (EL, MH, CB, PB, JDW). All
five observers were trained individuals with strong expertise in
gating the EuroFlow PIDOT tube and (routine) users of
Infinicyt™. Standard deviation (SD) and coefficient of variation
(CV) values were calculated for each cell population as obtained by
both gating strategies.
Statistical Methods
For comparison of the analysis strategies, Spearman rank
correlation was used. For comparison between groups for
continuous variables, the Chi-squared test with the Yates’
correction for continuity, was applied. Statistical comparison of
the CVs was performed by the variance ratio F-test. Two-sided p-
values <0.05 were considered to be associated with statistical
significance. In case of multiple testing, the Bonferroni
correction was applied. Statistical evaluation was performed
using MedCalc Statistical Software (version 15.6.1; MedCalc
Software bvba, Ostend, Belgium) and GraphPad Prism (version
5.04 for Windows; GraphPad Software, San Diego, CA).RESULTS
Comparison Between MG and AG&I
Approaches on Healthy Donor Blood
Samples
When considering all observations for the HD samples (n=520
observations; 20 cell populations in 26 samples), the vast majority of
the events in the HD FC standard data files—median of 99.85%
(range: 99.30–99.95%)—that corresponded to lymphoid cells were
classified into one of the lymphocyte populations of the database
with the AG&I module. In contrast, for a minor fraction of events—
median 0.15% (range 0.0–0.70%)—the AG&I module induced an
alarm due to phenotypic deviations from the reference populations
in the PIDOT database, and required revision by an expert.
Differences greater than 20% on absolute cell counts (/µL) as
calculated via MG vs AG&I were observed in 17% of all HD
observations. An overview of these differences per cell population is
shown in Table 2. Briefly, no differences >20% between both
analytical strategies (MG and AG&I) were observed for 9/20
lymphoid populations (i.e. total lymphocytes, B-cells, pre-GC B-
cells, T-cells, CD4+ T-cells, CD4+ naïve and central memory T-cells,
CD8+ T-cells, and TCRgd+ T-cells). In turn, a limited number ofTABLE 1 | Phenotypic features used in the Manual Gating (MG) strategy for the
identification of lymphoid populations in blood according to the EuroFlow
guidelines for analysis of blood samples stained with PIDOT.
Population Gating strategy (1)
B-cells FSClo SSCloCD45hiCD19+CD3-CD45RA+
Pre-germinal center B-cells CD27-IgD+IgM+
Post-germinal center B-cells/
plasmacells (MBC/PC)
Unswitched MBC/PC (2) IgD+IgM+CD27 +




TCRgd+ T-cells TCRgd +CD4-CD8- to lo
TCRgd- CD4-CD8- T-cells TCRgd -CD4-CD8- to lo
CD4+ T-cells TCRgd -CD4+CD8-
CD4+ naive T-cells CD27+CD45RA+
CD4+ central memory T-cells CD27+CD45RA-
CD4+ effector memory T-cells CD27-CD45RA-
CD4+ terminal effector T-cells CD27-CD45RA+
CD8+ T-cells TCRgd -CD4-CD8+
CD8+ naive T-cells CD27+CD45RA+
CD8+ central memory T-cells CD27+CD45RA-
CD8+ effector memory T-cells CD27-CD45RA-
CD8+ effector CD27+ T-cells CD27loCD45RA+
CD8+ terminal effector T-cells CD27-CD45RA+
CD4+CD8+ T-cells TCRgd -CD4+CD8+
Natural Killer cells SSC-AloFSC-AloCD45hiCD19-CD3-
CD16&CD56hiCD45RAlo to +(1)In addition to the classical two-dimensional gating based on the listed markers,
automatic population separator (APS) plots were used for fine-tune the gating of the
listed cell populations as described elsewhere (4); (2)Most MBC/PC, but not all, are CD27+.November 2020 | Volume 11 | Article 584646
TABLE 2 | Comparison of the Manual Gating (MG) strategy versus the AG&I module.








































































































































































































































































































































































































































































































































































































CVID, Common Variable Immunodeficiency Disorder patients; PID, Other PID patients; Non PID: patients with diseases other than PID; HD, healthy donors; Pre-GC-B-cells, pre

















Linskens et al. Automated Gating for FC PID ScreeningHD samples showed >20% differences between MG and AG&I
counts for NK-cells (n=3/26), unswitched memory B-cells/plasma
cells (MBC/PC) (n=8/26), switched MBC/PC (n=2/26), CD4+
effector memory T-cells (n= 2/26), CD8+ naive T-cells (n=2/26),
CD8+ central memory T-cells (n=5/26) and CD4-CD8- TCRgd- T-
cells (n=6/26). In contrast, differences were more frequently
observed [60% of the observations (n=62/104)] for other less
abundant T-cell subpopulations [CD4+ terminal differentiated
(TD) T-cells (n=20/26), CD8+ effector memory T-cells (n=11/26),
CD8+ TD27+ T-cells (n=19/26) and CD8+ TD T-cells], as might
have been expected for these populations which typically represent
<1% of all WBC. Of note, CD4+CD8+ double-positive T-cells were
not assigned as a separate population with the AG&I module.
Spearman rank correlation coefficients for cell populations
mandatory for PID screening and classification according to the
ESID criteria (i.e. total lymphocytes, total B-cells, pre-GC B-cells,
unswitched and switched MBC/PC, total T-cells, CD4+ and CD8+
T-cells, CD4+ and CD8+ naïve and central memory T-cells, TCRgd+
and TCRgd- CD4-CD8- T-cells, NK-cells) are shown in Table 3. For
healthy donor samples correlation coefficients of >0.90 were
obtained for most populations.
In order to further evaluate the impact of AG&I on both
intra- and inter-observer reproducibility of data analysis on HD
samples, SDs and median %CVs for MG and AG&I data, were
compared (see Figure 1A). As a result, a lower overall median %
CV was observed with the AG&I approach compared to MG (5.8
vs 0.2% for intra-observer and 8.0 vs 0.3% for inter-observer
reproducibility, respectively). A more detailed analysis of the
impact of AG&I for the individual cell populations is given in
Supplementary Table 1A.
Comparison of the MG Strategy Versus
the AG&I Module on Samples of Patients
Suspected of PID
A rather limited median percentage of checks (% of total events)
was observed with the AG&I module (median 0.54%; range:Frontiers in Immunology | www.frontiersin.org 60.02–41.5%) for all observations recorded on the patient samples
(n=880 observations for 20 cell populations in 44 samples)
(Supplementary Figure 1).
Around one third (32%) of all patient samples showed >20%
differences on the absolute cell counts (/µL) of at least one cell
population as obtained with MG vs the AG&I module, with
similar frequencies (p>0.05) in each of the three patient groups
(CVID 35%, other PID 34%, and non-PID 28%). Despite this,
differences >20% between both analytical strategies involving one
or more of the major lymphocyte populations in blood (total
lymphocytes, B-cells, T-cells, CD4+ and CD8+ T-cells) were
restricted to a minority (<15%) of all patient samples. Thus,
>20% differences were observed for total lymphocytes in 1/44
patients, B-cells in 1/44 cases, T-cells in 1/44, CD4+ T-cells in
2/44, and CD8+ T-cells in 5/44 cases. More than 20% differences
between MG vs AG&I observed in the patient samples were
mostly documented for the less abundant B- and T-cell
subpopulations (counts <1% of all WBC). An overview of the
results obtained per cell population is shown in Table 2.
Spearman rank correlation coefficients for patient samples
were calculated, showing correlation coefficients of >0.90 for
most subset populations mandatory for PID screening and
classification according to the ESID criteria (see Table 3).
The AG&I approach showed a greater intra- and inter-
observer reproducibility than MG also on patient samples with
lower median %CV (5.1 vs 0.4% for intra-observer and 12.1 vs.
0.6% for inter-observer reproducibility for AG&I vs MG,
respectively) for all 20 lymphoid populations identified (see
Figure 1B and Supplementary Table 1B).Impact of AG&I vs MG on Clinical
Interpretation of Results
The possible impact of differences on clinical interpretation of cell
counts obtained with the AG&I tool vs the MG strategy was
evaluated by comparing each of the paired counts against age-
matched reference percentile (p5–p95) ranges, assessed on a group
of 250 HD (4). Data are summarized in Table 2. Overall,
comparison of the results obtained with each of the two data
analysis approaches against age-matched reference values,
translated into different clinical interpretations for MG and AG&I
in only 4.4% (n=62/1,400) of all paired observations [1.3% (n=7/
520) for HD and 6% (n=55/880) for the patient samples].
Looking at the major lymphocyte populations (total
lymphocytes, B-cells and T-cells) in both HD and patient
samples, no difference in clinical interpretation was observed
after evaluating the results against the age-matched p5–p95
reference values. The clinically relevant differences were also
limited for the NK-cells, a different interpretation being
restricted to a single HD sample (absolute NK-cell counts
below p5 for MG while within the p5–p95 range for AG&I).
No differences in clinical interpretation related to the B-cell
populations were observed in HD. In contrast, several
differences in clinical interpretation were observed among
the patients. Thus, clinically relevant differences in pre-
germinal center B-cell counts were observed for one CVID
patient sample for which differences against age-matchedTABLE 3 | Correlation between absolute counts obtained by manual gating
(MG) versus automated gating and identification (AG&I).
Healthy donors Patients Total
Lymphocytes 0.996 0.994 0.994
B-cells 0.996 0.998 0.998
Pre-GC B-cells 0.997 0.992 0.995
Unswitched MBC/PC 0.955 0.845 0.877
Switched MBC/PC 0.983 0.963 0.956
T-cells 0.997 0.992 0.992
CD4+ T-cells 0.998 0.989 0.990
CD4+ naive T-cells 0.976 0.988 0.989
CD4+ central memory T-cells 0.960 0.933 0.923
CD8+ T-cells 0.995 0.980 0.991
CD8+ naive T-cells 0.987 0.978 0.983
CD8+ central memory T-cells 0.779 0.933 0.893
TCRgd+ T-cells 0.999 0.925 0.942
TCRgd- CD4- CD8- T-cells 0.951 0.915 0.955
Natural killer cells 0.883 0.983 0.973Results expressed as Spearman rank correlation coefficient values for those cell
populations that are mandatory for PID screening and classification according to the
ESID criteria. For all correlations p-vales < 0.001 were detected.November 2020 | Volume 11 | Article 584646
Linskens et al. Automated Gating for FC PID Screeningreference values were also detected for the memory B-cell
populations as discussed in more detail below (Sample 1).
Differences in clinical interpretation for unswitched and
switched MBC/PC were mostly observed among CVID (n=2)
and other PID samples (n=4; 2 KMT2A deficiencies, 1 IRAK4
deficiency, and 1 MBL). For the two KMT2A deficiency
patients, who typically display a CVID-like phenotype with
deviations in B-cell maturation and low absolute counts of
different B-cell populations, the absolute counts obtained
with MG were within age-matched reference ranges for
both unswitched and switched MBC/PC, while AG&I
provided decreased absolute counts for both memory B-cell
populations below the p5. The IRAK4 deficiency sample and
MBL deficiency sample (both conditions for which no
lymphoid deviations are usually expected) also showed
clinically relevant differences for the unswitched MBC/PC
subpopulation, with abnormal values for the MG approach
(below p5 for the IRAK4 deficiency and above p95 for the MBL
deficiency), but normal absolute counts for all B-cell
subpopulations when analyzed with the AG&I tool. In
addition, another CVID patient sample (not Sample 1, see
above), showed a clinically relevant difference in the absolute
number of unswitched MBC/PC: decreased below p5 with MG
while within the normal range with the AG&I approach. In
another CVID sample, different clinical interpretation for
switched MBC/PC was made with AG&I (absolute values
below p5 as is expected for a CVID phenotype) and MG
(absolute values within the p5–p95 range).Frontiers in Immunology | www.frontiersin.org 7Differences in clinical interpretation related to CD4+ T-cell
populations (including the less abundant CD4+ T cell
populations) were also absent in HD and very limited in patient
samples (0–7% of samples depending on the specific CD4+ T-cell
population). No clinically relevant differences were found in HD
for naive and central memory CD8+ T-cells, with only a few
discrepancies in patient samples (between 5% and 9% of the
samples depending on the specific CD8+ T-cell population).
More differences in clinical interpretation (compared with age-
matched normal p5–p95 reference ranges) were observed for the
CD8+ effector T-cell populations (range: 7–27% of samples
depending on the specific cell population). Despite all the above,
detailed analysis of all clinically relevant differences observed for
the distinct T-cell populations identified with PIDOT, showed no
recurrent pattern (or cause) in all but one sample. This latter
sample corresponded to a non-PID sample (Sample 2) which
showed a combined pattern of clinically relevant differences in
both CD4+ memory effector T-cells and CD4-CD8- TCRgd-
T-cells, as discussed in more detail below.
Different clinical interpretation for the TCRgd+ and CD4-
CD8- TCRgd- T-cells were observed for a limited number of
samples (1 and 6, respectively). One of these samples was already
described above (Sample 2). In addition, one CVID sample
(Sample 3) showed clinically relevant differences for both
TCRgd+ and CD4-CD8- TCRgd- T-cells, triggering further
investigations (see below). For the remaining four discrepant
samples, no underlying cause could be identified to clarify
the difference.A
B
FIGURE 1 | Intra- and inter-observer reproducibility of Manual Gating (MG) versus Automated Gating and Identification (AG&I). (A; top figure) Box-and-Whisker plots
of CVs (%) for all lymphoid populations in HD blood samples. (B; bottom figure) Box-and-Whisker plots of CVs (%) for all lymphoid populations in patient samples.
****Statistically significant differences (P < 0.0001) based on the variance ratio F-test.November 2020 | Volume 11 | Article 584646
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Discrepancies
Detailed revision of both MG and AG&I data analysis was
performed for all samples showing “clinically relevant”
differences on the interpretation of the results obtained (once
compared with age-matched reference values) for at least one
lymphoid cell population (differences in 62 observations
corresponding to 37 samples). In 34/37 samples (92%) AG&I
results were confirmed during the expert review. In the
remaining three samples (8%) corresponding to two CVID
samples [Sample 1 and 3] and one non-PID patient sample
[Sample 2] AG&I results were questionable. In more detail, in
one of these two CVID samples [Sample 1], different absolute
counts were observed for all B-cell populations identified by MG
vs AG&I. Plots corresponding to the (unchecked) AG&I analysis
for this sample are shown in Figure 2A. This was due to the fact
that by AG&I a large proportion of the B-cells was automatically
assigned to the memory IgD+IgM- B-cell population. MG
confirmed that phenotypically this population was indeed
CD27+; however, its phenotype was not fully compatible with
the classically high IgD expression (MFI of between 104 – 105
using the EuroFlow instrument settings in combination with the
EuroFlow PIDOT reagents) on memory IgD+IgM- B-cells,
making their distinction from switched MBC/PC (CD27+/
IgM-/IgD-) a challenge, also with MG that assigned them to
switched MBC/PC. Despite this uncommon phenotype, AG&I
analysis did not classify these events as ‘checks’. In the other two
discordant samples (Samples 2 and 3) clinically relevant
differences for the CD4-CD8- TCRgd- T-cell population were
observed and confirmed after revision of the AG&I data. In the
latter CVID sample (Sample 3), a large TCRgd+ population was
automatically assigned to the CD4-CD8- TCRgd- population by
AG&I (unchecked AG&I plots shown in Figure 2B). In the non-
PID sample (Sample 2), events classified by MG as CD4+ effector
memory T-cells and CD4+ naive T-cells had been incorrectly
classified by the AG&I module as CD4-CD8- TCRgd- due to an
abnormally low CD4-signal because of a technical (staining)
issue (unchecked AG&I plots shown in Figure 2C). Despite all
the above, these wrongly identified cell populations were
systematically alarmed as “numerically altered” by the AG&I
software tool, pointing out the need for review by the expert prior
to final reporting.DISCUSSION
Due to major technological advances in multiparameter FC, data
analysis has become increasingly complex and time-consuming
(13, 18, 21–23). This also implies higher variability and more
subjectivity, as it is influenced by the observer’s expertise. Thus,
the increased complexity associated with greater numbers of cells
measured for an increasingly high number of parameters with
the ability of identifying greater numbers of cell populations, has
fostered the development of automated algorithms and tools for
the analysis of complex multiparameter FC datasets (14, 18, 21–Frontiers in Immunology | www.frontiersin.org 823). In this study, we evaluated the contribution of the EuroFlow
AG&I module implemented in the Infinicyt software for analysis
of PB samples stained with PIDOT in the standardization of the
FC diagnostic work-up of PID.
Overall, our results showed that compared to MG, the use of
the AG&I approach was associated with a significantly lower
intra- and inter-observer variability of data analysis (and also
interpretation) for all lymphoid populations identified with the
PIDOT. In fact, the use of the AG&I tool systematically provided
for most lymphoid populations identified a high intra- and inter-
observer reproducibility with <20% CVs according to the EN ISO
15189 criterion applied in most European medical diagnostics
laboratories (20). Altogether, these results indicate that
replacement of MG by the AG&I module would be associated
with a greater reproducibility and robustness of results.
In turn, a high degree of agreement (defined as <20%
numerical differences in absolute cell counts/µL) was
obtained between expert-based MG and the AG&I module,
for most lymphocyte populations in both HD (83% of all
observations) and routine diagnostic patient samples (68% of
all observations), most discrepancies occurring for cell
populations present at low (<1%) frequencies in blood. This
translated into a minimal possible impact (4.4% of all
observations, 6.3% of patient observations, 1.3% of HD
observations) on the final clinical interpretation (e.g. normal
vs increased or decreased cell counts) resulting from the
comparison of the results obtained with each analytical
approach with (p5–p95) age-matched reference values.
Thereby, only a limited number of discordant observations
between MG and AG&I was detected for those lymphoid
populations that are mandatory for PID screening according
to the ESID criteria (i.e. total lymphocytes, total B-cells, pre-GC
B-cells, unswitched and switched MBC/PC, total T-cells, CD4+
and CD8+ T-cells, CD4+ and CD8+ naïve and central memory
T-cells, TCRgd+ and TCRgd- CD4-CD8- T-cells, NK-cells). For
those lymphoid populations, discrepant observations were
restricted to 4.4% of patients observations (n=29/660
observations) and 0.2% of HD observations (n=1/390). This
was due to the fact that most differences were observed for the
less abundant T-cell populations (e.g. CD4+ and CD8+ effector
memory and terminally differentiated T-cells), that are
currently not considered in the (routine) diagnostic work-up
of PID.
Looking into potential reasons for the discrepancies here
reported between AG&I and MG, we identified three different
variables to contribute to such differences: low absolute counts,
suboptimal light scatter measurements and the use of single
heterogeneously expressed markers for the distinction between
two lymphoid populations. Thus, several of the less abundant T-
cell subpopulations had low absolute counts for those samples
with a >20% difference between AG&I and MG (Mann-Whitney
U, p<0.05, see Supplementary Data Table 2). Besides, EuroFlow
recommends well defined intervals for median FSC-A and/or
SSC-A values for lymphocytes (median FSC-A of >50,000/
<60,000 and median SSC-A of >11,000/<13,000). Here we
observed that when these criteria were violated, an increasedNovember 2020 | Volume 11 | Article 584646
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MG was found (see Supplementary Data Tables 2 and 3). For B-
cells, the high number of >20% AG&I vs. MG differences
observed for unswitched memory B-cells (and pre-GC B cells)
could be related to the fact that these two B-cell populations are
discriminated among them based upon a single marker/
parameter with heterogeneous expression levels (i.e. CD27).
This was confirmed by the significant lower delta MFI for
CD27 between pre-GC and unswitched memory B-cells in theFrontiers in Immunology | www.frontiersin.org 9discrepant FC standard data file cases (median MFI values of 999
vs. 2441 arbitrary fluorescence channel values, Mann-Whitney U
p=0.043) and vice versa (Supplementary Data Figure 2).
Overall, these results indicate that AG&I is more reproducible
and more accurate than MG in detecting abnormal values for
individual cell populations (see below) due to technical issues,
including those populations that are mainly discriminated based
on a single, heterogeneously expressed marker (e.g. CD27 in
unswitched memory B-cells vs pre-germinal center B-cells).A
B
C
FIGURE 2 | Representative (unchecked) AG&I bivariate dot-plots corresponding to the specific cell populations present in those 3 cases with altered phenotypes
identified during detailed expert revision. (A) CVID sample (Sample 1) with a B-cell population showing abnormally dim expression of IgD on IgM-negative B-cells,
classified by the AG&I tool as IgD+IgM- MBC/PC (brown) with need for expert revision based on their aberrant expression pattern, in addition to pre-germinal center
B-cells (dark green), unswitched MBC/PC (bright green) and switched MBC/PC (blue). (B) CVID sample with a large population of TCRgd+ T-cells (see arrow)
incorrectly assigned CD4-CD8- TCRgd- events (orange) (sample 3) in addition to CD8+ T-cells (green), CD4+ T-cells (purple) and TCRgd+ T-cells (blue). (C) Non PID
patient with a large population of dim CD4+ events (see arrow) automatically classified as CD4-CD8- TCRgd- T-cells (orange) (sample 2), in addition to CD8+ T-cells
(green) and CD4+ T-cells (pink).November 2020 | Volume 11 | Article 584646
Linskens et al. Automated Gating for FC PID ScreeningThus, these data indicate that strict adherence to the EuroFlow
SOPs and criteria for instrument setup and calibration is
mandatory, including a systematic check of the light scatter
characteristics of lymphocytes for individual samples before
final data storage, in parallel to careful evaluation of cell
populations with low absolute count results.
Taken together, our results indicate that compared to
conventional expert-based MG, routine use of the AG&I tool is
associated with both a greater reproducibility of data analysis
and a more robust interpretation of the numerical alterations
detected for those lymphoid cell populations that are relevant in
the diagnostic work-up of PID of the lymphoid system. However,
for PID diagnosis, FC results should not be interpreted based on
alterations involving single cell populations, but rather on the
combination of altered patterns that typically affect >1 cell
population within a sample.
As indicated above, numerical clinically relevant differences
between AG&I and MG were more frequently observed among
the patient samples than in HD samples. These results might be
due to the fact that abnormal B- and T-cell maturation patterns
and/or marker expression profiles are virtually restricted to
patient samples and such altered profiles frequently represent a
challenge during data analysis, even when MG is performed by
an experienced operator. Indeed, clinically relevant differences
within the B-cell subpopulations were found in several PID
patients included in this study. For these PID patient-
associated differences, it remains difficult to define which
gating approach is correct due to the lack of a reference
standard and the limited number of patients analyzed.
Nevertheless, our results suggest a more accurate gating of B-
cell populations using AG&I vs MG, since using the AG&I
approach, B-cell alterations were only detected in the KMT2A-
deficient patients, which are expected to have a CVID-like
phenotype (24), but not in the IRAK4-deficient and MBL-
deficient patients for whom no lymphoid deviations are usually
expected (2, 9). Altogether, these findings underline the need for
robust reference databases of PIDOT-stained blood samples
from well-defined PID patients, in addition to normal HD
blood, for unequivocal and accurate classification of cell events
in PID suspicious patient blood samples, ideally generated in
multi-center settings, as initiated by the EuroFlow PID
consortium (4, 6, 13, 14, 25). Moreover, the availability of
reference images of PID patients to the database might also
contribute to a better classification of the more challenging cell
populations and cases.
Despite all the above, the AG&I approach used here, based
on the PIDOT database composed of HD blood samples
stained with PIDOT at multiple centers, separately classifies
all clusters of events that show phenotypic deviations from
normal as groups of events that need to be checked by an
expert. For HD samples, only a minor proportion of all events
contained in the individual FC data files (<1% events) were
classified as “checks”, i.e. events mimicking lymphoid cells
that required expert revision following the AG&I classification
tool. This observation is in line with previously published data
on HD blood samples stained with other EuroFlow antibodyFrontiers in Immunology | www.frontiersin.org 10combinations, that typically showed <2% checks of the
total events (14). In contrast, some cell populations which
are either absent or present at very low frequency in
normal blood, such as activated B- and T-cells, might
require expert revision, particularly for patient samples, as
confirmed here.
Optimal use of the AG&I module for PIDOT would imply
that in a first step, only unclassified clusters of events should be
checked by an expert. Subsequently, all cell populations that
carry phenotypic and/or numerical alarm should be revised, as
done in this study for 37 samples that showed >20% differences
in the absolute cell counts obtained for at least one cell
population with the AG&I approach vs MG, that led to a
distinct clinical interpretation after comparison with p5–p95
age-matched reference ranges (normal vs altered cell
population). In all except three of these 37 samples, extended
expert revision of the AG&I gating approach revealed no error.
In the three remaining samples aberrant maturation and/or
abnormal marker expression profiles were seen which might
have induced an arguable classification of specific cell
populations by the AG&I tool leading in all three cases to
numerical alarms (i.e. absolute counts of the corresponding cell
populations falling outside age-matched normal reference
ranges). Thus, in a routine clinical laboratory setting, these
latter deviations would trigger expert revision of the
immunophenotypic results prior to their integration with other
laboratory data and clinical findings. Although the underlying
reason for these phenotypic deviations could not be fully
identified, they might be due, at least in part to technical issues
related with the quality of staining with single liquid format
reagents (e.g. CD4 staining in one case, IgD staining in another
patient and TCRgd staining in third patient). In order to limit the
impact of reagent variability and minimize pipetting issues,
EuroFlow encourages the use of the lyophilized format of the
PIDOT reagents (10).
In summary, here we show that the AG&I tool contributes to
the standardization of FC data analysis in the diagnostic work-up
of PID suspected patients, mostly due to its improved
reproducibility vs conventional expert-based MG approaches
and a more robust definition of numerical alterations against
age-matched reference ranges. However, expert revision of the
results of AG&I of PIDOT data still remains necessary in samples
with numerical alterations and aberrant B- and T-cell maturation
and/or abnormal marker expression profiles. Importantly,
diagnosis of PID requires integration of FC results with other
laboratory data (e.g. serum immunoglobulin levels, functional
assays, molecular diagnostics, vaccination response), clinical
findings and clinical history (e.g. history of infections),
according to both the ESID and IUIS criteria (2, 6, 9). Of note,
this study specifically focused on the evaluation of the technical
performance of the new AG&I module for analysis of PIDOT
data in a rather limited cohort of healthy donor and patient
samples. Therefore, the overall impact of the new AG&I
approach on the final PID diagnosis still remains to be fully
defined in larger patient cohorts that include a wide variety of
PID patients, preferably in a multi-center setting.November 2020 | Volume 11 | Article 584646
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